1.	p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage Phase: Phase IV Type: Treatment Status: Active Age: 18 to 85 Sponsor: Pharmaceutical / Industry Protocol IDs: rAd-p53-001, NCT00894153
2.	Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Head and Neck Cancer to Prevent Aspiration Pneumonia Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCNONCO201007, NCT01598402
3.	18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology Phase: Phase III Type: Diagnostic Status: Active Age: 19 to 90 Sponsor: Other Protocol IDs: R05-0076, NCT00207298
4.	Tranexamic Acid and Head and Neck Surgery Patients Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 20 to 80 Sponsor: Other Protocol IDs: TCVGH-957001A, 941117/C05186, NCT00308880
5.	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00507, E1305, CDR0000582533, U10CA021115, ECOG-E1305, NCT00588770
6.	Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Phase: Phase III Type: Supportive care Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: TADDOR, CSET 1388, NCT00935675
7.	Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EUDRACT NUMBER 2009-013402-14, NCT00999700
8.	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000675520, NCCTG-N09C6, N09C6, NCT01156142
9.	Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397 Phase: Phase III Type: Biomarker/Laboratory analysis Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000715505, ECOG-E5397T3, E5397T3, NCT01466244
10.	Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours Phase: Phase II, Phase I Type: Diagnostic Status: Active Age: 16 and over Sponsor: Other Protocol IDs: SP-14-0050/DX-FAZ-001/22390, NCT00323076
11.	Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 603EUSA03, NCT00901732
12.	Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 06-121, 1R21CA130241-01A1, NCT00903461
13.	A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WCI1761-09, NCT01283334
14.	A Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
15.	E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7050-702, 2011-000773-31, NCT01332266
16.	Immune Therapy of HPV-induced Cancers Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VicOryx, NCT01462838
17.	Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 21 and over Sponsor: NCI, Other Protocol IDs: OSU-07085, NCI-2011-03226, R01CA127368, NCT01469429
18.	Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: CTRC 11-47, HSC20120131H, NCT01592721
19.	A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBYL719X2104, 2011-006017-34, NCT01602315
20.	Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage III-IV Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02009, A091101, U10CA031946, N01CM62201, NCT01711541
21.	PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 12-1972, NCI-2013-00586, NCT01816984
22.	Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors Phase: Phase II Type: Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: HSC-MS-04-259, NCT00178698
23.	MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer Phase: Phase II Type: Supportive care Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 76,770, NCT00252174
24.	DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: DAHANCA 20, NCT00400426
25.	Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients Phase: Phase II Type: Supportive care Status: Active Age: 18 and over Sponsor: Other Protocol IDs: eschiff, NCT00408759